Boehringer Ingelheim: Stroke trials
The registry lists 23 Stroke studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 15 have results posted.
Phase 2 2Phase 3 7Phase 4 3No phase 11(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Alteplase Treatment in Elderly Acute Ischaemic Stroke (AIS) PatientsCompletedNCT05401149Results posted
- Alteplase in Elderly Acute Ischemic Stroke (AIS) Patients During HospitalizationCompletedNCT05395351Results posted
- 1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) PatientsCompletedNCT05395338Results posted
- A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical ActivityCompletedNCT04915729Phase 3Results posted
- Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;CompletedNCT04290494Results posted
- Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke OnsetCompletedNCT02930837Phase 3Results posted
- Patient Convenience Study (RE-SONANCE)CompletedNCT02684981Results posted
- Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)CompletedNCT02239120Phase 3Results posted
- GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)CompletedNCT01671007Results posted
- GLORIA-AF Registry Program - Second and Third PhasesCompletedNCT01468701Results posted
- EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASACompletedNCT00562588Phase 4Results posted
- JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin ProgrammeCompletedNCT00311402Phase 3Results posted
- Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran EtexilateCompletedNCT00262600Phase 3Results posted
- Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048TerminatedNCT00157248Phase 2Results posted
- PRoFESS - Prevention Regimen For Effectively Avoiding Second StrokesCompletedNCT00153062Phase 4Results posted
- Safety and Tolerability of BIII 890 in Patients With Acute Ischemic StrokeCompletedNCT02251197Phase 2
- An International Observational Study of the Safety and Efficacy of Thrombolysis in StrokeCompletedNCT02229890
- Safe Implementation of Thrombolysis in Stroke - Monitoring StudyCompletedNCT02229812
- Protocol for Post Marketing Surveillance of Actilyse VialTerminatedNCT02229799
- Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic StrokeTerminatedNCT02184260Phase 4
- GLORIA-AF Registry Program (Phase II/III)CompletedNCT01937377
- Headache Study to Compare Aggrenox Full Dose and Reduced DoseCompletedNCT00274586Phase 3
- Rt-PA in the Treatment of Acute Ischemic StrokeCompletedNCT00153036Phase 3